about
Cyclooxygenase-2 expression and inhibition in atherothrombosisNovel determinants of plaque instabilityThromboxane-dependent CD40 ligand release in type 2 diabetes mellitusOxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm.Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome.COX-2 and prostaglandins in atherosclerosis.Role of angiotensin II receptor blockers in atherosclerotic plaque stability.Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk.COX-2 and atherosclerosis.COX-2 and the vasculature: angel or evil?COX-2 expression in atherosclerosis: the good, the bad or the ugly?Platelets in atherothrombosis: new and evolving roles.Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.Cyclooxygenase and atherosclerosis: a smoking area.MicroRNAs and atherosclerosis: new actors for an old movie.Laminar shear stress regulates endothelial kinin B1 receptor expression and function: potential implication in atherogenesis.Effects of nabumetone on prostanoid biosynthesis in humans.Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy.Guidelines enforcement and clinical outcome.Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria.A unique microRNA signature associated with plaque instability in humans.Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy.A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E.Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity.Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans.Effects of vitamin E supplementation on intracellular antioxidant enzyme production in adolescents with type 1 diabetes and early microangiopathy.Letter by Santovito et al regarding article, "rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation".EP receptors and coxibs: seeing the light at the end of the tunnel.Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control.Association between 5-lipoxygenase expression and plaque instability in humans.Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy.Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design.Cox-2 polymorphisms and cardiovascular disease: elucidating the hidden side of the disease.Genetic and molecular determinants of atherosclerotic plaque instability.Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques.
P50
Q28165912-981E5EC1-BC72-4175-A18B-D8BC4100CAD9Q28187632-D508651C-C65B-42F7-9F37-6FF850DB5F4FQ28194498-1B2AACD6-5C27-4F7D-8010-91064624C6ADQ34017497-2932C533-4D8B-468B-B6FB-F12B7B872E22Q34171028-CD749420-9BCE-44DC-9461-6D98FA45EC79Q36283503-2148A496-EDA0-43E3-8D0C-9C9CFA752C4EQ36382568-07DA1A93-F0F1-4BC3-A901-D2E30584A48AQ36461104-6C09FDBE-4681-46BC-9D72-EEC4558E9FCAQ36512084-13B09895-9722-49B2-A47F-F3BAEADD8FB9Q36760539-C67229F5-3C53-47E1-99F3-04F01A57227AQ36855485-6AD4036C-6A74-4378-AA34-0BA0A74080FFQ36855627-95A1B04C-BE1B-4EED-8ACE-AB8008E7F36EQ37235902-C6C9F318-F800-4085-B4FE-578E994AEC84Q37373486-7C9D1F77-6767-4BDE-8031-B74505F06CB1Q37765294-60221634-0C04-4951-A154-FC85E9246157Q38022837-59848B76-98D5-4B34-9C80-438A14DE8E16Q41882128-AD411D2F-ADB9-44FA-8E45-C246E691F72AQ42276009-0FFF6C6A-F4D0-481B-B55A-43A510D271B2Q43015761-11B6A38B-F692-4FA6-846D-A9808309308AQ43088267-442884E7-0237-4636-B74C-D60D38341C21Q43640930-12225302-3FE2-47B5-828F-CA5C82B3D9A7Q43659268-F9ACBB2B-B8C2-4B18-B0FA-73011B744E27Q43766873-F07A8471-5D52-46A9-B169-80E39F7CE1A6Q44075631-45FEDE2D-231C-4B0D-B4E4-144A1C2C454FQ44103563-128F1E42-2CCF-4F0E-BA6E-88B426E21F01Q44213374-869EB3E7-5178-422C-9E6F-709D7185D324Q44374274-B8817D0A-B623-48A5-B81C-689FDB7BB01EQ44545480-1D462912-73C4-4102-A72A-9C7E6AB4E406Q44810028-64AB3E29-09F0-4AB9-AB4E-17B384565C22Q44904582-9200F05E-429F-4BE0-AB2E-75214706DEFDQ45044372-EAB19B60-3A6B-4DF9-AB03-4BBE658A8745Q45181370-FA755000-299E-49D1-A9E8-E33D3C9C0B8EQ46271114-F4ADDE80-CBB8-4896-A7AF-0A8FFAA39919Q46469540-2EB8B454-6A3C-4552-924B-383CFFE342E5Q46525384-73CF9B2F-47E9-4D53-92E3-22B3CF42CAB1Q46570734-32C3125E-F07B-440D-92D0-C40617216F9DQ48425884-CA99C133-3EE2-476A-9EF1-346DCDDE85D5Q48461020-D9FC1A46-BF53-490E-BA4B-C5AB9D23C82FQ50334555-E3EBC45F-3076-4A6C-9819-1C91ADEAEEA1Q50789641-7568AB50-C902-428F-8036-6838490860DB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesco Cipollone
@ast
Francesco Cipollone
@en
Francesco Cipollone
@es
Francesco Cipollone
@sl
type
label
Francesco Cipollone
@ast
Francesco Cipollone
@en
Francesco Cipollone
@es
Francesco Cipollone
@sl
prefLabel
Francesco Cipollone
@ast
Francesco Cipollone
@en
Francesco Cipollone
@es
Francesco Cipollone
@sl
P106
P1153
7003611260
P21
P31
P496
0000-0002-5993-9341